Literature DB >> 448557

The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice.

F W Henderson, W A Clyde, A M Collier, F W Denny, R J Senior, C I Sheaffer, W G Conley, R M Christian.   

Abstract

To develop a broad understanding of the causes and patterns of occurrence of wheezing associated respiratory infections, we analyzed data from an 11-year study of acute lower respiratory illness in a pediatric practice. Although half of the WARI occurred in children less than 2 years of age, wheezing continued to be observed in 19% of children greater than 9 years of age who had lower respiratory illness. Males experienced LRI 1.25 times more often than did females; the relative risk of males for WARI was 1.35. A nonbacterial pathogen was recovered from 21% of patients with WARI; respiratory syncytial virus, parainfluenza virus types 1 and 3, adenoviruses, and Mycoplasma pneumoniae accounted for 81% of the isolates. Patient age influenced the pattern of recovery of these agents. The most common cause of WARI in children under 5 years of age was RSV whereas Mycoplasma pneumoniae was the most frequent isolate from school age children with wheezing illness. The data expand our understanding of the causes of WARI and are useful to diagnosticians and to researchers interested in the control of lower respiratory disease.

Entities:  

Mesh:

Year:  1979        PMID: 448557     DOI: 10.1016/s0022-3476(79)80647-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  65 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

Review 2.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

Review 3.  Lower airway obstruction in the PICU.

Authors:  S A Kecskes
Journal:  Indian J Pediatr       Date:  1990 Mar-Apr       Impact factor: 1.967

4.  Pathogenesis of bronchiolitis and pneumonia induced in neonatal and weanling rats by parainfluenza (Sendai) virus.

Authors:  W L Castleman; L J Brundage-Anguish; L Kreitzer; S B Neuenschwander
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

Review 5.  Epidemiology of asthma and recurrent wheeze in childhood.

Authors:  Anne L Wright
Journal:  Clin Rev Allergy Immunol       Date:  2002-02       Impact factor: 8.667

6.  Acute respiratory admissions in Thessaloniki, Greece: 14-year follow-up.

Authors:  E Hatziagorou; F Kirvassilis; S Saraphidou; M Katsara; R Valeri; M Emporiadou; C Magnisali; J Tsanakas
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

Review 7.  Pathogenesis of lower respiratory tract infections due to Chlamydia, Mycoplasma, Legionella and viruses.

Authors:  P Andersen
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

8.  Genomewide association analysis of respiratory syncytial virus infection in mice.

Authors:  James M Stark; M Michael Barmada; Abby V Winterberg; Nilanjana Majumber; William J Gibbons; Marilyn A Stark; Maureen A Sartor; Mario Medvedovic; Jay Kolls; Kiflai Bein; Beena Mailaparambil; Marcus Krueger; Andrea Heinzmann; George D Leikauf; Daniel R Prows
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses.

Authors:  Richard Singleton; Nathalie Etchart; Sam Hou; Lisa Hyland
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Alterations in pulmonary ultrastructure and morphometric parameters induced by parainfluenza (Sendai) virus in rats during postnatal growth.

Authors:  W L Castleman
Journal:  Am J Pathol       Date:  1984-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.